419 related articles for article (PubMed ID: 22179316)
41. Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors.
Gabery S; Sajjad MU; Hult S; Soylu R; Kirik D; Petersén Å
Eur J Neurosci; 2012 Sep; 36(6):2789-800. PubMed ID: 22731249
[TBL] [Abstract][Full Text] [Related]
42. Dysregulation of REST-regulated coding and non-coding RNAs in a cellular model of Huntington's disease.
Soldati C; Bithell A; Johnston C; Wong KY; Stanton LW; Buckley NJ
J Neurochem; 2013 Feb; 124(3):418-30. PubMed ID: 23145961
[TBL] [Abstract][Full Text] [Related]
43. Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons.
Zala D; Colin E; Rangone H; Liot G; Humbert S; Saudou F
Hum Mol Genet; 2008 Dec; 17(24):3837-46. PubMed ID: 18772195
[TBL] [Abstract][Full Text] [Related]
44. Modulation of mTOR and CREB pathways following mGluR5 blockade contribute to improved Huntington's pathology in zQ175 mice.
Abd-Elrahman KS; Ferguson SSG
Mol Brain; 2019 Apr; 12(1):35. PubMed ID: 30961637
[TBL] [Abstract][Full Text] [Related]
45. Reduced Expression of Foxp1 as a Contributing Factor in Huntington's Disease.
Louis Sam Titus ASC; Yusuff T; Cassar M; Thomas E; Kretzschmar D; D'Mello SR
J Neurosci; 2017 Jul; 37(27):6575-6587. PubMed ID: 28550168
[TBL] [Abstract][Full Text] [Related]
46. Suppression of protein aggregation by chaperone modification of high molecular weight complexes.
Labbadia J; Novoselov SS; Bett JS; Weiss A; Paganetti P; Bates GP; Cheetham ME
Brain; 2012 Apr; 135(Pt 4):1180-96. PubMed ID: 22396390
[TBL] [Abstract][Full Text] [Related]
47. Rescue of gene expression by modified REST decoy oligonucleotides in a cellular model of Huntington's disease.
Soldati C; Bithell A; Conforti P; Cattaneo E; Buckley NJ
J Neurochem; 2011 Feb; 116(3):415-25. PubMed ID: 21105876
[TBL] [Abstract][Full Text] [Related]
48. Mechanisms for neuronal cell death and dysfunction in Huntington's disease: pathological cross-talk between the nucleus and the mitochondria?
Sawa A
J Mol Med (Berl); 2001 Jul; 79(7):375-81. PubMed ID: 11466559
[TBL] [Abstract][Full Text] [Related]
49. In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons.
Thomas EA; Coppola G; Tang B; Kuhn A; Kim S; Geschwind DH; Brown TB; Luthi-Carter R; Ehrlich ME
Hum Mol Genet; 2011 Mar; 20(6):1049-60. PubMed ID: 21177255
[TBL] [Abstract][Full Text] [Related]
50. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes.
Zuccato C; Tartari M; Crotti A; Goffredo D; Valenza M; Conti L; Cataudella T; Leavitt BR; Hayden MR; Timmusk T; Rigamonti D; Cattaneo E
Nat Genet; 2003 Sep; 35(1):76-83. PubMed ID: 12881722
[TBL] [Abstract][Full Text] [Related]
51. Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in Huntington's disease transgenic mice.
Pang TYC; Stam NC; Nithianantharajah J; Howard ML; Hannan AJ
Neuroscience; 2006 Aug; 141(2):569-584. PubMed ID: 16716524
[TBL] [Abstract][Full Text] [Related]
52. Electroconvulsive shock ameliorates disease processes and extends survival in huntingtin mutant mice.
Mughal MR; Baharani A; Chigurupati S; Son TG; Chen E; Yang P; Okun E; Arumugam T; Chan SL; Mattson MP
Hum Mol Genet; 2011 Feb; 20(4):659-69. PubMed ID: 21106706
[TBL] [Abstract][Full Text] [Related]
53. Loss of huntingtin function slows synaptic vesicle endocytosis in striatal neurons from the htt
McAdam RL; Morton A; Gordon SL; Alterman JF; Khvorova A; Cousin MA; Smillie KJ
Neurobiol Dis; 2020 Feb; 134():104637. PubMed ID: 31614197
[TBL] [Abstract][Full Text] [Related]
54. MeCP2: a novel Huntingtin interactor.
McFarland KN; Huizenga MN; Darnell SB; Sangrey GR; Berezovska O; Cha JH; Outeiro TF; Sadri-Vakili G
Hum Mol Genet; 2014 Feb; 23(4):1036-44. PubMed ID: 24105466
[TBL] [Abstract][Full Text] [Related]
55. Amelioration of Huntington's disease phenotypes by Beta-Lapachone is associated with increases in Sirt1 expression, CREB phosphorylation and PGC-1α deacetylation.
Lee M; Ban JJ; Chung JY; Im W; Kim M
PLoS One; 2018; 13(5):e0195968. PubMed ID: 29742127
[TBL] [Abstract][Full Text] [Related]
56. The neuroprotective effects of Tanshinone IIA are associated with induced nuclear translocation of TORC1 and upregulated expression of TORC1, pCREB and BDNF in the acute stage of ischemic stroke.
Liu L; Zhang X; Wang L; Yang R; Cui L; Li M; Du W; Wang S
Brain Res Bull; 2010 May; 82(3-4):228-33. PubMed ID: 20417695
[TBL] [Abstract][Full Text] [Related]
57. Msh2 acts in medium-spiny striatal neurons as an enhancer of CAG instability and mutant huntingtin phenotypes in Huntington's disease knock-in mice.
Kovalenko M; Dragileva E; St Claire J; Gillis T; Guide JR; New J; Dong H; Kucherlapati R; Kucherlapati MH; Ehrlich ME; Lee JM; Wheeler VC
PLoS One; 2012; 7(9):e44273. PubMed ID: 22970194
[TBL] [Abstract][Full Text] [Related]
58. ATF3 plays a protective role against toxicity by N-terminal fragment of mutant huntingtin in stable PC12 cell line.
Liang Y; Jiang H; Ratovitski T; Jie C; Nakamura M; Hirschhorn RR; Wang X; Smith WW; Hai T; Poirier MA; Ross CA
Brain Res; 2009 Aug; 1286():221-9. PubMed ID: 19559011
[TBL] [Abstract][Full Text] [Related]
59. Neurodegeneration. Huntington's research points to possible new therapies.
Marx J
Science; 2005 Oct; 310(5745):43-5. PubMed ID: 16210515
[No Abstract] [Full Text] [Related]
60. Mutant huntingtin activates Nrf2-responsive genes and impairs dopamine synthesis in a PC12 model of Huntington's disease.
van Roon-Mom WM; Pepers BA; 't Hoen PA; Verwijmeren CA; den Dunnen JT; Dorsman JC; van Ommen GB
BMC Mol Biol; 2008 Oct; 9():84. PubMed ID: 18844975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
